{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:isaralgagene civaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:cotoretigene toliparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:giroctocogene fitelparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:zocaglusagene nuzaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
USAN:COBNABEXAGENE ANVUPARVOVEC HEXB [USAN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
USAN:COBNABEXAGENE ANVUPARVOVEC HEXA [USAN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:ixoberogene soroparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:bevufenogene nofeparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:pariglasgene brecaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04566445: Phase 2 Interventional Active, not recruiting Dry Age-related Macular Degeneration
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE